Concentration of Risk

BIOGEN INC.

Low

BIIB · Nasdaq · Biological Products, (No Diagnostic Substances) · CIK 0000875045

Latest filing: 10-K · 2026-02-06

Customer concentration

Significant Customers note · revenue dependency

Low
Top exposure
<10%
No disclosure detected
Flat

Geographic concentration

Segment reporting · geographic revenue

Low
Top exposure
<10%
No disclosure detected
Flat

Supplier concentration

Risk Factors · supply chain dependency

Low
Dependency
Third party for biosimilar
Third party for biosimilar productsNamed
Qualitative disclosure — no % quantified (informational, not scored)
Flat
FY25

Qualitative dependency level by filing year.

Product concentration

ASC 275 · disclosed dependence on a specific product or service

Low
Top exposure
10%
TYSABRINamed
Products disclosed
SPINRAZA10%
TYSABRI10%
Flat

Click a point to open the SEC source

FY250%3%6%9%12%

Credit concentration

ASC 825 · concentration of credit risk note

Low
Receivables
<10%
Diversified
Flat